Smith & Nephew: The Discount That Reached the Doctors

In the Smith & Nephew FCPA case, the parent company agreed to pay more than $5.4 million in a civil Securities and Exchange Commission settlement over allegations that its subsidiaries used a distributor to bribe Greek public-hospital doctors. The alleged payments looked like marketing expenses, while the doctors controlled purchases of the company’s medical devices. For someone who knows the distributor, the discount approvals or the supposed marketing work, the case connects familiar business records to the people the money was meant to influence.

The Securities and Exchange Commission announced the settlement on February 6, 2012. Its Foreign Corrupt Practices Act case concerned Smith & Nephew PLC, the London-based parent, and conduct involving its U.S. and German subsidiaries. A separate criminal agreement concerned the U.S. subsidiary, Smith & Nephew Inc.

The Doctor Was Also the Public Customer

Smith & Nephew sold orthopedic products in Greece through a local distributor. According to the SEC’s account of its complaint, the U.S. subsidiary and Smith & Nephew Orthopaedics GmbH in Germany had used that distributor since the 1970s. The case grew out of the SEC’s and the Justice Department’s broader investigation of medical-device companies’ payments to publicly employed physicians.

The medical-device bribery issue was built into the sales relationship. The Securities and Exchange Commission described a Greek national health care system in which most hospitals were publicly owned and operated, with their doctors employed by the government. Those doctors were the foreign officials in the agency’s allegations, and purchasing Smith & Nephew products was the decision the alleged payments sought to influence.

The Securities and Exchange Commission’s 2015 speech, FCPA, Disclosure, and Internal Controls Issues Arising in the Pharmaceutical Industry, explains why those sales contacts matter. Public-hospital doctors, pharmacists and administrators often decide which products their institutions buy. The speech’s discussion of payments for prescribing expressly includes medical devices. A sales employee may therefore know the official through routine product discussions, orders and hospital business.

How the Distributor Discount Became a Payment Pool

The distributor discount funded the alleged scheme through a separate payment route. In the Justice Department’s account, the criminal information charged that Smith & Nephew Inc., through executives, employees and affiliates, agreed to sell products at full list price to an Athens-based distributor. The amount of the distributor discount then went to an offshore shell company that the distributor controlled.

The criminal information charged that the distributor used those funds for cash incentives and other benefits to publicly employed Greek healthcare providers to induce purchases. The Justice Department’s account said some or all of the money paid to the shell companies went to physicians.

That arrangement gives an insider something specific to recognize. A product sale could show the full list price while the discount traveled to a different payee controlled by the distributor. The commercial relationship, the discount authorization and the bank destination tell connected parts of the story.

The SEC speech explains why distributor margins deserve this attention. It describes how a distributor can use its margin or spread to create a cash fund for bribes, with another layer of cash flow helping the payments appear as legitimate expenses. Smith & Nephew’s alleged route puts that industry problem into a recognizable transaction: a real device sale and a separate payment to a shell company.

Marketing Services With No Marketing Work

The SEC alleged that Smith & Nephew’s subsidiaries began making payments to three distributor-controlled shell entities in the United Kingdom in 1997. The agency said the arrangement created offshore funds that were not subject to Greek taxes, to pay bribes to public doctors. It described the supposed purpose as marketing services, then stated the problem plainly:

The alleged arrangement gave the money a business label while buying no marketing work at all. We call that buying the buyer: the SEC described an expense for promoting the product that concealed a payment to the person choosing it.

The Securities and Exchange Commission also described an email exchange about reducing the distributor’s commissions. According to the agency, the distributor told employees at the U.S. subsidiary that he was paying cash incentives immediately after each surgery. Smith & Nephew Inc. decided against reducing the commissions. The agency’s account puts the explanation of cash payments alongside a decision to preserve the rate.

For a finance or sales insider, this is where the accounting and control questions become more useful than a general warning about third parties. The relevant comparison is the service description against the work performed, the commission discussion against the explanation of cash payments, and the warning against the decision that followed. The SEC alleged that employees at the company and its subsidiaries became aware of the payments and that Smith & Nephew failed to act on numerous warning signs.

The Parent’s SEC Settlement and the Subsidiary’s Criminal Agreement

The Justice Department’s account of the criminal information put the payments authorized to the distributor’s shell companies from 1998 through 2008 at approximately $9.4 million. Against that payment pool, the parent agreed to a civil settlement of more than $5.4 million with the Securities and Exchange Commission.

The Justice Department identified Smith & Nephew PLC as an English company traded on the New York Stock Exchange. The criminal agreement concerned its wholly owned U.S. subsidiary, Smith & Nephew Inc.

In describing the subsidiary’s deferred prosecution agreement, the Justice Department said Smith & Nephew Inc. acknowledged responsibility for improper payments by affiliates, subsidiaries, employees and agents to publicly employed Greek healthcare providers. That account ties the subsidiary’s responsibility to the people acting through the distribution business, including the agents who dealt with the doctors.

The Same Disguise in Other Healthcare Cases

Fresenius Medical Care supplies a close parallel because its SEC order describes the accounting benefit of moving payments into a supplier’s costs. In its settled findings, the SEC said a finance director justified lost revenue because a West African supplier was absorbing phony commission payments to doctors. The order explains what that did to the company’s books:

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA examines how third parties and distributorships concealed payments to public-hospital decision-makers. Its discussion of West Africa connects those arrangements with unsupported transactions, falsified accounting records and failures by compliance and internal audit to detect or prevent the conduct. The comparison sharpens the Smith & Nephew question: a payment’s description in the manufacturer’s accounts can conceal what happens inside the intermediary.

Olympus Latin America admitted under its deferred prosecution agreement that agent payments in Mexico were recorded as administrative or advisory services for public bids even though the services were neither performed nor required. Novartis Hellas admitted under its deferred prosecution agreement that congress sponsorship for Greek public-sector eye doctors was exchanged for increased prescribing. The commercial form differed, but each account connects a benefit to the public healthcare decision the company wanted.

What an Insider May Recognize

The evidence that connects these transactions may sit with people doing ordinary sales, distribution or finance work. A discount approval explains the amount released, a payee record identifies where it went, and the claimed marketing work explains how the expense was presented. An email about commissions can connect those records to knowledge inside the business. We work with insiders to connect their part of that account to the purchasing decision and the people who approved the payments.

For foreign-bribery information, SEC whistleblower awards can total 10% to 30% of the money collected in qualifying enforcement actions. We assess your information and bring in FCPA whistleblower lawyers whose expertise fits the conduct you saw. For separate fraud against U.S. government money, a whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Marketing Payment Bought

If you know why a distributor’s discount went to another company, or why marketing bills had no work behind them, speak to one of our Whistleblower Experts about where the discount went. We build the case around your knowledge of the sales and payments, bring in FCPA whistleblower lawyers who understand medical-device distribution, and stay beside you throughout the case.